Cincinnati Children's Hospital Medical Center
AGTC's potential treatment for Alpha-1 Antitrypsin Deficiency is in Phase II testing at the Cincinnati Children's Hospital Medical Center.

Foundation Fighting Blindness
The mission of the Foundation Fighting Blindness, Inc. (FFB) is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa (RP), macular degeneration, Usher syndrome, and the entire spectrum of retinal degenerative diseases. AGTC has partnered with the FFB on several projects to complete proof of concept work needed to advance treatments for various retinal degenerative diseases to the clinic.

Genzyme Corporation
In 2004 AGTC entered into a collaboration with Genzyme Corporation of Cambridge, MA to develop an AAV treatment for Age-Related Macular Degeneration (AMD). Pre-clinical studies showed the product to be safe (mice, rats and primates) and efficacious (mice and primates). In March of 2010, coinciding with the initiation of a Phase I human clinical trial, the collaboration was converted to a license agreement by which Genzyme is fully responsible for further development of the product. Enrollment in the trial is proceeding and the DSMB has approved escalation of the product dose as planned.

The University of Florida
AGTC has extensive ties to The University of Florida's Powell Gene Therapy Center and has multiple Sponsored Research Contracts at the University. These contracts cover basic research for many new product candidates as well as projects that will enhance the basic AAV technology platform.
-Powell Gene Therapy Center
-University of Florida

University of Massachusetts
Two of AGTC's product candidates, treatments for Alpha-1 Antitrypsin Deficiency and Leber Congenital Amaurosis, are in Phase II testing at The University of Massachusetts Medical School. It is one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $240 million in research funding annually, 80 percent of which comes from federal funding sources. The mission of the Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. For more information, visit www.umassmed.edu.

University of Pennsylvania
AGTC works closely with researcher's at the University of Pennsylvania's Immunology Core under the direction of Dr. James Wilson and Dr. Roberto Calcedo to understand the immunology of AAV vectors used in both animal and human studies.

Oregon Health Science University
AGTC's potential treatment for Leber Congenital Amaurosis is in Phase II testing at the Casey Eye Institute. As part of Oregon Health & Science University, the Casey Eye Institute is an academic regional eye center. It is named after James and George Casey, founders of United Parcel Service. The Casey Eye Institute is also one of only seven regional eye research centers in the nation sponsored by Research to Prevent Blindness, the world's leading voluntary organization in support of eye research. The Casey Eye Institute has operated the Elks Children's Eye Clinic since 1949, thanks to the generous support of the Oregon State Elks Association.